IMM47 / ImmuneOnco Biopharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  IMM47 / ImmuneOnco Biopharma
    Enrollment open, Metastases:  A Study Of IMM47 In Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Oct 4, 2023   
    P1,  N=48, Recruiting, 
    Not yet recruiting --> Recruiting
  • ||||||||||  IMM47 / ImmuneOnco Biopharma
    Preclinical development of a monoclonal antibody targeting CD24 as cancer immunotherapy (Section 22; Poster Board #16) -  Mar 14, 2023 - Abstract #AACR2023AACR_8525;    
    Our data has also confirmed that IMM47 specifically binds to and induces ADCC (antibody-dependent cellular cytotoxicity) ,ADCP (antibody-dependent cellular phagocytosis), and CDC (complement-dependent cytotoxicity) against a variety of cancer cells. Taken together, our data show that targeting CD24 on tumor cells using our IMM47 antibody may serve as potent immunotherapy for multiple cancer indications.